Opportunity Information: Apply for PAR 13 327
Apply for PAR 13 327
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (SBIR R43/44)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research 93.396 Cancer Biology Research.
- This funding opportunity was created on Aug 8, 2013 and posted on Aug 8, 2013.
- Applicants must submit their applications by May 27, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
- Other Eligible Applicants include the following Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity. A small business concern is one that, at the time of award of Phase I and Phase II, meets all of the following criteria 1. Is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor 2. Is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture 3. (i) SBIR and STTR. Be a concern which is more than 50 percent directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50 percent directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these OR (ii) SBIR only. Be a concern which is more than 50 percent owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these. No single venture capital operating company, hedge fund, or private equity firm may own more than 50 percent of the concern OR (iii) SBIR and STTR. Be a joint venture in which each entity to the joint venture must meet the requirements set forth in paragraph 3 (i) or 3 (ii) of this section. A joint venture that includes one or more concerns that meet the requirements of paragraph (ii) of this section must comply with 121.705(b) concerning registration and proposal requirements. 4. Has, including its affiliates, not more than 500 employees. If the concern is more than 50 percent owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these falls under 3 (ii) or 3 (iii) above, see Section IV. Application and Submission Information for additional instructions regarding required application certification. If an Employee Stock Ownership Plan owns all or part of the concern, each stock trustee and plan member is considered an owner.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (SBIR R43/44) opportunity (Funding Opportunity Number PAR 13-327) is a National Institutes of Health grant announcement designed to help US small businesses develop and commercialize new, cancer-relevant molecular and cellular analysis technologies. The basic idea is to fund projects that push beyond incremental improvements by creating genuinely innovative tools that can either solve long-standing technical roadblocks in cancer research and clinical care or enable entirely new directions in how cancer is studied, detected, diagnosed, and treated. While the announcement aligns with the National Cancer Institute's Innovative Molecular Analysis Technologies (IMAT) program, companies do not need prior IMAT participation to apply, and the focus is explicitly on building a credible path from R&D into a real product or service.
The FOA targets technology development that improves the way researchers and clinicians analyze cancer at the molecular and/or cellular level. In practice, that can include platforms or methods that generate better biological measurements (for example, higher sensitivity, improved specificity, increased throughput, lower cost, less invasive sampling, better spatial or single-cell resolution, faster turnaround time, or improved robustness in real-world clinical environments). The emphasis is on technologies with a strong justification that they are meaningfully better than existing options, not just different. Applications are expected to clearly explain what makes the proposed approach distinctive, what concrete advantages it offers over conventional methods and currently available technologies, and why those advantages matter for cancer research or patient care.
This is an SBIR mechanism using the R43/R44 pathway, meaning it supports the typical SBIR phased structure: Phase I generally demonstrates feasibility and reduces key technical risks, while Phase II supports further development and validation toward commercialization. A central expectation of the FOA is that applicants define clear, measurable milestones that cover both technical development and commercialization readiness. In other words, reviewers are looking for more than strong science; they want to see a disciplined plan that lays out what success looks like at each stage, how performance will be assessed, what development benchmarks will be met, and how the project will move toward a marketable product (including items such as prototype development, validation studies, manufacturability considerations, usability, regulatory planning when relevant, and early customer or partner discovery).
Eligibility is limited to United States small business concerns, and the FOA lays out the standard SBIR requirements. To qualify, the business must be for-profit, have a place of business in the US, and operate primarily in the US or make a significant contribution to the US economy through taxes or the use of American products, materials, or labor. The company must be an allowable legal entity type (such as a sole proprietorship, partnership, LLC, corporation, joint venture, association, trust, cooperative) and must have no more than 500 employees including affiliates. Ownership and control must meet SBIR rules, including pathways that allow majority ownership by US individuals/permanent residents, or certain venture-capital-majority structures permitted under SBIR as long as no single VC/hedge/private equity firm owns more than 50 percent, with additional joint venture conditions if applicable.
From a topic and mission perspective, the funded work can fall across a wide range of cancer-related areas reflected in the CFDA listings, including cancer cause and prevention research (93.393), detection and diagnosis (93.394), treatment research (93.395), and cancer biology (93.396). There is no cost sharing or matching requirement, which typically makes the program more accessible for early-stage companies that need non-dilutive funding to de-risk core technology components.
Key administrative details from the listing include the original posting date of August 8, 2013, with an original and final closing date of May 27, 2016 (the opportunity is archived as of June 27, 2016). The sponsoring agency is NIH, and the full announcement was provided through the NIH grants guide at the linked page. For technical issues accessing or linking to the announcement, the NIH Office of Extramural Research webmaster contact is provided.
In plain terms, this FOA was meant for small US companies building next-generation cancer analysis tools that can realistically become commercial products, with a strong preference for high-impact innovations backed by a concrete development plan, explicit technical and business milestones, and a clear explanation of why the technology is a step-change over what is already on the market or in standard practice.
Frequently Asked Questions (FAQs)
1) What is this funding opportunity?
This is the NIH Small Business Innovation Research (SBIR) funding opportunity titled "Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (SBIR R43/44)," Funding Opportunity Number PAR 13-327. It was designed to support U.S. small businesses developing and commercializing new molecular and cellular analysis technologies relevant to cancer research and clinical care.
2) What is the main goal of PAR 13-327?
The goal is to fund technology development that goes beyond incremental improvements by creating genuinely innovative tools. The program aims to support technologies that can remove long-standing technical bottlenecks in cancer research/clinical care or enable entirely new ways to study, detect, diagnose, and treat cancer, with a credible plan to reach a real product or service.
3) What types of technologies does the FOA focus on?
The FOA targets molecular and/or cellular analysis technologies that improve how cancer is analyzed in research and clinical settings. Examples of desired improvements include higher sensitivity, improved specificity, increased throughput, lower cost, less invasive sampling, better spatial or single-cell resolution, faster turnaround time, and improved robustness in real-world clinical environments.
4) Is the focus on research-only tools, clinical tools, or both?
Both. The announcement supports technologies that improve cancer research and/or clinical care, as long as the application clearly explains why the technology matters for cancer research or patient care and how it could transition into a marketable product or service.
5) What does the FOA mean by "innovative" versus "incremental"?
The emphasis is on step-change advances rather than small tweaks. Applications are expected to justify that the proposed approach is meaningfully better than existing options, not merely different, and to explain what concrete advantages it offers over conventional methods and currently available technologies.
6) What SBIR mechanism is used for this opportunity?
This FOA uses the SBIR R43/R44 pathway, which follows the typical phased SBIR structure: Phase I generally demonstrates feasibility and reduces key technical risks, and Phase II supports further development and validation toward commercialization.
7) What are reviewers looking for beyond strong science?
In addition to scientific/technical merit, reviewers are looking for a disciplined development plan with clear, measurable milestones that cover both technical progress and commercialization readiness. The FOA stresses defining what success looks like at each stage and how performance will be assessed.
8) What kinds of milestones are expected?
Applicants are expected to propose measurable milestones tied to both development and commercialization. The FOA highlights areas such as prototype development, validation studies, manufacturability considerations, usability, regulatory planning when relevant, and early customer or partner discovery.
9) Do companies need prior participation in the IMAT program to apply?
No. While the FOA aligns with the National Cancer Institute's Innovative Molecular Analysis Technologies (IMAT) program, prior IMAT participation is not required to apply.
10) Who is eligible to apply?
Eligibility is limited to United States small business concerns under standard SBIR requirements. The business must be for-profit, have a place of business in the U.S., and operate primarily in the U.S. or make a significant contribution to the U.S. economy through taxes or the use of American products, materials, or labor.
11) What types of legal business entities can qualify?
The FOA notes allowable entity types consistent with SBIR rules, including sole proprietorships, partnerships, LLCs, corporations, joint ventures, associations, trusts, cooperatives, and similar structures, as long as SBIR eligibility requirements are met.
12) Is there an employee size limit?
Yes. The company must have no more than 500 employees, including affiliates, to qualify as an SBIR-eligible small business concern.
13) What ownership and control rules apply?
Ownership and control must meet SBIR rules. The FOA description references pathways that allow majority ownership by U.S. individuals/permanent residents, as well as certain venture-capital-majority structures permitted under SBIR, provided no single VC/hedge/private equity firm owns more than 50 percent, with additional joint venture conditions if applicable.
14) What cancer topic areas can projects cover?
The funded work can fall across a wide range of cancer-related areas reflected in CFDA listings, including cancer cause and prevention research (93.393), detection and diagnosis (93.394), treatment research (93.395), and cancer biology (93.396).
15) Is cost sharing or matching required?
No. The listing states there is no cost sharing or matching requirement.
16) What is the commercialization expectation?
A central expectation is a credible path from R&D to a real product or service. The FOA emphasizes moving beyond technical development alone by incorporating commercialization readiness milestones and planning (for example, manufacturability, usability, regulatory planning when relevant, and early market discovery activities).
17) What is the status of this opportunity?
The opportunity is archived. The listing includes an original posting date of August 8, 2013, with an original and final closing date of May 27, 2016, and it is archived as of June 27, 2016.
18) Who is the sponsoring agency?
The sponsoring agency is the National Institutes of Health (NIH).
19) Where was the full announcement published?
The full announcement was provided through the NIH grants guide at the referenced page in the listing.
20) Who should be contacted for technical issues accessing the announcement?
For technical issues accessing or linking to the announcement, the listing provides the NIH Office of Extramural Research webmaster contact.
21) What kinds of performance improvements does NIH want to see justified?
The FOA expects applicants to clearly state how the technology improves biological measurements and why those improvements matter. Examples in the description include sensitivity, specificity, throughput, cost, invasiveness of sampling, spatial or single-cell resolution, turnaround time, and robustness in clinical environments.
22) What does the FOA expect applicants to explain about competing methods?
Applications are expected to explain what makes the proposed approach distinctive, what concrete advantages it offers over conventional methods and currently available technologies, and why those advantages matter for cancer research or patient care.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: FY14 16 CRCP Fishery Management Council Coral Reef Conservation Cooperative Agreements
Previous opportunity: 2014 NIH Directors New Innovator Award Program (DP2)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 13 327
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 13 327) also looked into and applied for these:
| Funding Opportunity |
|---|
| Revisions for Early Stage Development of Informatics Technology (P01) Apply for PAR 13 330 Funding Number: PAR 13 330 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Health Promotion Among Racial and Ethnic Minority Males (R21) Apply for PA 13 331 Funding Number: PA 13 331 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01) Apply for PAR 13 334 Funding Number: PAR 13 334 Agency: National Institutes of Health Category: Education Health Funding Amount: $3,000,000 |
| Neuroscience Research on Drug Abuse (R21) Apply for PA 13 337 Funding Number: PA 13 337 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Neuroscience Research on Drug Abuse (R03) Apply for PA 13 336 Funding Number: PA 13 336 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Neuroscience Research on Drug Abuse (R01) Apply for PA 13 338 Funding Number: PA 13 338 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Mechanisms of Alcohol and Stimulant Co Addiction (R01) Apply for PA 13 339 Funding Number: PA 13 339 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Mechanisms of Alcohol and Stimulant Co Addiction (R21) Apply for PA 13 340 Funding Number: PA 13 340 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Early Career Award in Chemistry of Drug Abuse and Addiction (ECHEM) (R21/R33) Apply for PAR 13 350 Funding Number: PAR 13 350 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| National Institute on Drug Abuse National Early Warning System (NEWS) Coordinating Center (U01) Apply for RFA DA 14 015 Funding Number: RFA DA 14 015 Agency: National Institutes of Health Category: Education Health Funding Amount: $900,000 |
| Research Answers to NCIs Provocative Questions Group A (R01) Apply for RFA CA 13 016 Funding Number: RFA CA 13 016 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research Answers to NCIs Provocative Questions Group A (R21) Apply for RFA CA 13 017 Funding Number: RFA CA 13 017 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Research Answers to NCIs Provocative Questions Group B (R01) Apply for RFA CA 13 018 Funding Number: RFA CA 13 018 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research Answers to NCIs Provocative Questions Group C (R01) Apply for RFA CA 13 020 Funding Number: RFA CA 13 020 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research Answers to NCIs Provocative Questions Group D (R01) Apply for RFA CA 13 022 Funding Number: RFA CA 13 022 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research Answers to NCIs Provocative Questions Group D (R21) Apply for RFA CA 13 023 Funding Number: RFA CA 13 023 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Research Answers to NCIs Provocative Questions Group B (R21) Apply for RFA CA 13 019 Funding Number: RFA CA 13 019 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Research Answers to NCIs Provocative Questions Group C (R21) Apply for RFA CA 13 021 Funding Number: RFA CA 13 021 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Research Answers to NCIs Provocative Questions Group E (R01) Apply for RFA CA 13 024 Funding Number: RFA CA 13 024 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research Answers to NCIs Provocative Questions Group E (R21) Apply for RFA CA 13 025 Funding Number: RFA CA 13 025 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 13 327", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.